JAN 2 8 2005 55

MM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO .: SERIAL NO .: PATENT AND TRADEMARK OFFICE CD0787Q1 10/786,886 APPLICANT: INFORMATION DISCLOSURE STATEMENT David R. Andrews et al. BY APPLICANT FILING DATE: GROUP: (Use several sheets if necessary) 02/25/2004 1624 U.S. PATENT DOCUMENTS EXAMINER DOCUMENT DATE CLASS SUB-FILING DATE IF INITIAL NUMBER **CLASS** APPROPRIATE FB AA 5,625,064 4/1997 Andrews et al. 544 366 AB 5,661,151 8/1997 Saksena et al. 514 252 AC 5,693,626 12/1997 Saksena et al. 514 85-ΑD 5,703,079 12/1997 Saksena et al. 514 252 5,710,154 ΑĒ 1/1998 Saksena et al. 252 514 AF 5,714,490 2/1998 Saksena et al. 252 514 FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUB-TRANSLATION NUMBER CLASS YES NO PCT AG WO 95/17407 6/1995 AH WO 96/33178 10/1996 PCT WO 96/38443 Al 12/1996 PCT AJ WO 93/09114 5/1993 PCT AK WO 99/15522 4/1999 PCT AL WO 99/32128 7/1999 PCT OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AM | Munzel, Von K., Progress in Drug Research, 10:227-230, Birkhauser, Basel, Switzerland (1996) **EXAMINER** DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

05

Genlinal